# Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

> **NCT03345043** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 156 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** VAL-339851
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03345043
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2018-08-13
- **Final completion:** 2018-08-13
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345043, "Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03345043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*